Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 EMA approvals of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekirax + Exviera (ombitasvir/paritaprevir/ritonavir + dasabuvir), have ushered in the era of interferon (IFN)-free direct-acting antiviral (DAA) therapy for chronic HCV infection and completely reshaped the HCV therapeutic market. The EMA’s recent authorization of Gilead’s Epclusa (sofosbuvir/velpatasvir) provides the first FDC approved for all HCV genotypes. Hepatitis C Virus | Access & Reimbursement | EU5 examines the market access factors that influence the success of IFN-free DAA therapies in the EU5 markets. The series is based on primary research with EU5 gastroenterologists and hepatologists, as well as country-specific payers. This research explores how payers and physicians interact and how reimbursement decisions influence the prescribing and uptake of specific therapies at the brand level.